Related Experiment Video
Updated: Jun 1, 2026
A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
Published on: February 2, 2024
[The relationship between hepatocellular carcinoma recurrence and hepatitis B virus recurrence after liver
Min-ru Li1, Shu-hong Yi, Chang-jie Cai
1Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Insights
Hepatocellular carcinoma (HCC) recurrence after liver transplantation is a significant risk factor for hepatitis B virus (HBV) recurrence. Patients with HCC recurrence face a higher incidence of HBV recurrence post-transplant.
Area of Science:
- Hepatology
- Transplantation Medicine
- Virology
Context:
- Hepatitis B virus (HBV) infection is a leading cause of end-stage liver disease and hepatocellular carcinoma (HCC).
- Liver transplantation is a curative option for advanced HBV-related liver disease.
- Managing post-transplant recurrence of both HBV and HCC is critical for patient outcomes.
Purpose:
- To investigate the relationship between hepatocellular carcinoma (HCC) recurrence and hepatitis B virus (HBV) recurrence following liver transplantation.
- To identify risk factors associated with HBV recurrence in patients with HBV-related end-stage liver disease.
Summary:
- A retrospective analysis of 340 patients undergoing liver transplantation for HBV-related end-stage liver disease revealed HBV recurrence in 33 patients.
- Multivariate Cox regression identified HCC recurrence (HR=2.98) and pre-transplantation HBV-DNA load >5 log10 copies/ml (HR=3.99) as significant risk factors for HBV recurrence.
- Patients with HCC recurrence exhibited a higher incidence of HBV recurrence (27.9% vs. 8.7%) and a strong correlation between HCC and HBV recurrence times (r=0.583).
Impact:
- Post-transplantation HCC recurrence is confirmed as a significant risk factor for HBV recurrence.
- Findings highlight the importance of monitoring for HBV recurrence in liver transplant recipients, particularly those with a history of HCC.
- This study provides crucial insights for optimizing post-transplant management strategies to mitigate HBV recurrence.
Objective:
To investigate the relationship between hepatocellular carcinoma (HCC) recurrence and hepatitis B virus (HBV) recurrence.
Methods:
The clinical data of 340 patients underwent liver transplantation due to HBV related end-stage liver disease and received long-term follow up in our hospital from Jan 2004 to Dec 2008 were retrospectively analyzed. All patients received nucleoside analogues therapy formally before entering into the waiting list and nucleoside analogues combined low-dose HBIG therapy during and after transplantation. Patients were regularly followed up at the outpatient, monitoring the HBV recurrence and survival. Multivariate Cox regression analysis was used to evaluate the risk factors for hepatitis recurrence.
Results:
33 patients suffered from HBV recurrence post transplantation. The 1-, 3- and 5- year recurrence rates were 7.0%, 10% and 13% respectively. The median HBV recurrence time was 5 months (1-21 months). COX regression analysis revealed that risk factors for HBV recurrence were HCC (HR = 2.98; 95% CI 1.08-8.25; P < 0.05) and pre-transplantation HBV-DNA load over 5 log10 copies/ml (HR = 3.99; 95% CI 1.85-8.62; P < 0.01). Further stratified analysis showed that patients who suffered from carcinoma recurrence had a higher incidence of HBV recurrence than those who did not, which were 27.9% and 8.7% (HR = 4.58;95% CI 1.88-11.12; P < 0.01) respectively. 12 patients suffered from both HCC and HBV recurrence. Spearman correlation analysis demonstrated a strong correlation between HBV and HCC recurrence times (r = 0.583, P < 0.05).
Conclusions:
Post transplantation HCC recurrence is a risk factor for HBV recurrence.
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction